FindTrial
Sign In

FHD-286

DRUG3 trials

Sponsors

Foghorn Therapeutics Inc., Montefiore Medical Center

Conditions

Acute Myeloid LeukemiaAdvanced Hematologic MalignancyMetastatic Uveal MelanomaMyelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic SyndromesRelapsed Acute Myeloid Leukemia

Phase 1

FHD-286 in Subjects With Metastatic Uveal Melanoma
TerminatedNCT04879017
Foghorn Therapeutics Inc.Metastatic Uveal Melanoma
Start: 2021-05-11End: 2023-11-30Updated: 2024-04-25
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Active, not recruitingNCT04891757
Foghorn Therapeutics Inc.Advanced Hematologic Malignancy, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia +4
Start: 2021-06-14End: 2027-06-30Target: 144Updated: 2025-07-10
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RecruitingNCT07283094
Montefiore Medical CenterAcute Myeloid Leukemia, Myelodysplastic Syndrome
Start: 2026-02-03End: 2030-02-01Target: 33Updated: 2026-03-03

Related Papers

Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies
Blood2025-11-03
Machine learning-powered integration of global proteomics and ex vivo sensitivity unveils a protein signature predictive of treatment success to AML therapy: Validation in patients treated with FHD-286, a SMARCA2/4 dual inhibitor
Blood2025-11-03
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Clinical Cancer Research2025-04-165 citations
Preclinical efficacy of BRG1/BRM ATPase inhibitor in B lymphoblastic leukemia.
Journal of Clinical Oncology2024-06-011 citations
Abstract A041: FHD-286, a potent and selective inhibitor of BRG1 and BRM, shifts metastatic uveal melanoma tumor towards a less immunosuppressive state in patient samples
Molecular Cancer Therapeutics2023-12-01
Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies
Blood2023-11-0220 citations
888 Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models
Regular and Young Investigator Award Abstracts2022-11-012 citations
Abstract LB190: Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML
Cancer Research2022-06-15